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Take home messages: Rare subgroup of renal carcinoma should no more be study as a global 
entity. We would have been able to investigate the really infrequent metastatic ChRCC with 
collaborative groups. Our study confirms that these patients have very favorable prognosis and 
that VEGF inhibition is a good option of treatment in clinical practice. 
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Abstract 
 
Background: Treatment of non-clear cell RCC remains controversial, despite several 
recent prospective dedicated studies of targeted therapies (TT). Extrapolating the benefit of 
VEGF and mTOR inhibitors from the others subtype of kidney cancer, patients are routinely 
treated as clear cell RCC. 
Objective: to assess the clinical outcome associated with the use of targeted therapy in 
metastatic chromophobe (ChRCC) tumors. 
Design, setting, and participants: A retrospective data analysis was performed within the 
Renal cross Chanel group to determine metastatic ChRCC treatment outcomes in the targeted 
therapy era. Kaplan-Meier and summary statistics were used. Overall survival rates and overall 
response rates were calculated. 
Results and limitations: 91 mChRCC patients from 26 centers in 4 countries had been 
diagnosed between July1997 and April 2013 with a median follow-up from date of first 
metastasis of 6.1 years (range: 0-13.9). Median overall survival was 37.9 months (95%CI: 21.4 to 
46.8) from diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) 
were treated with VEGF TT and 11 with mTOR inhibitors. TTF in patients who received a first 
line antiangiogenic (AA) was 8.7 months (95%CI: 5.2-10.9) and median OS was 22.9 months 
(95%CI: 17.8-49.2). 
Conclusion: We report the largest cohort of patients with mChRCC treated with targeted 
therapy. Our results highlight the activity of VEGF inhibition in terms of TTF and OS in 
mChRCC. 
 
Patient summary: Our study focused on a very rare subtype of renal cancer (ChRCC) with 
metastatic disease. We have collected 91 cases within a European consortium in order to 
investigate SDWLHQW¶VFKDUDFWHULVWLFVprognosis and outcome with currently available systemic 
therapy. 
 
 
Key words: chromophobe RCC, non-clear cell RCC, anti angiogenic 
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Introduction 
 
Over the past 12 years, therapeutic arsenal against renal cell carcinoma (RCC) has widely 
expanded, increasing patient survival with median overall survival reaching almost 30 months in 
recent studies1. However, most of the data have been reported in clear cell RCC. Despite several 
prospective dedicated studies of targeted therapies in non-clear cell RCC, the benefit of target 
therapies in the others subtypes remains unclear. Chromophobe renal cell carcinoma (ChRCC) is 
the most  common form  of non-clear cell RCC (nccRCC) (4 - 6%), after papillary RCC (10 - 15 
%)2. Many others rare histologies belong to this group, including collecting duct carcinoma 
(about 1%) and unclassified RCC (4 - 5 %). Various studies have demonstrated some efficacy of 
systemic therapies targeting VEGF and mTOR pathways, and  to date little is known about the 
activity of more recently monoclonal antibody directed toward the programmed death (PD 1)/ 
programmed death ligand 1 (PDL 1) pathway3 as well as dual new tyrosine kinase inhibiting 
MET and VEGFR24 in nccRCC. Recently 2 randomised studies investigated a pool of mixed 
non-clear cell histologies and few prospective trials focused on papillary RCC (pRCC); 
nevertheless evidence based recommendations about systemic therapy for metastatic ChRCC 
(mChRCC) are limited. 
First described by Thoenes in 1985, ChRCC probably derives from the collecting duct 
system from the intercalated cells5, it has been associated with better prognosis than other 
subtypes. Large surgical cohorts suggested that localised ChRCC display a more favourable 
prognosis with fewer metastatic spreading. Patard et al showed that ChRCC patients had a better 
outcome compared to papillary or clear cell RCC6. In this series, only 6 patients out of 396 
(1.5%) with ChRCC had distant disease. In another large retrospective database of 291 ChRCC, 
only 25 patients with ChRCC (8.6%) developed recurrence and 18 (6.2%) died from disease7. 
Similarly, other small cohorts reported a low rate of specific mortality and recurrence of 2% and 
6%, respectively in a serie of 50 patients with ChRCC with a mean follow up of 6 years8or no 
UHFXUUHQFHLQDSDWLHQW¶VFRKRUWZLWKDIROORZRI\HDUV9.  
Most of the available data in mChRCC comes from retrospective small series or rare phase 2 
enrolling heterogeneous population of non ccRCC. No standard of care is currently proposed for 
mChRCC patients in both NCCN or ESMO guidelines[A1]10,11. Extrapolating the benefit of VEGF 
and mTOR inhibitors to the others subtypes of kidney cancers, patients are routinely treated 
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similarly to clear cell RCC. In our study, we focused on metastatic ChRCC patients to assess the 
clinical outcome associated with the use of targeted agents. 
 
Materials and Method 
 
Study design and population 
 
In 2012, the initiative was carried out to conduct a retrospective chart review of mChRCC 
patients treated within the French kidney group of the GETUG (GURXSHG¶(WXGHGHV7XPHXUV
Uro genitales) and the Renal Cross Chanel Group (RCCG). Eligibility criteria included adult 
patients who had measurable disease by RECIST (Response Evaluation Criteria in Solid Tumors) 
and received TT. ChRCC diagnosis was performed by local pathology assessment. Standardized 
chart review collected date of diagnosis, age at diagnosis, gender, date of first metastasis, number 
and type of metastatic site at the initiation of systemic therapy and prognostic factors according to 
the IMDC risk model12. 
 
Statistical Analyses 
 
7KHSDWLHQWV¶FKDUDFWHULVWLFVVH[DJHDWGLDJQRVLV.36QXPEHURIPHWDVWDVHV,0'& 
risk model, MSKCC classification, prior nephrectomy and grade) were described (median and 
interquartile (IQR) for continuous variables and frequency for categorical variables) in TT 
patients and overall. Median follow-up was estimated by WKH6FKHPSHU¶VPHWKRGfrom the date of 
first-line therapy for patients treated with TT. For TT patients, the different types of TT classified 
as AA (sunitinib, sorafenib, pazopanib and bevacizumab) or mTOR (temsirolimus, everolimus) 
and the number of lines were reported. The best response (by local assessment) was determined 
every 8-12 weeks according to RECIST 1.1 criteria as complete response (CR), partial response 
(PR), stable disease (SD) and progressive disease (PD) and the objective response rate (ORR) 
defined as CR/PR, SD or PD were described. The latter was compared between the 2 classes of 
targeted WKHUDSLHVE\D)LVKHU¶VH[DFWWHVW7KHWLPHWRIDLOXUH77)ZDVGHILQHGDVWKHWLPHIURP
the date of first-line therapy to discontinuation of treatment for any reason, including disease 
progression, treatment toxicity, and death whichever occurred first. Patients with no treatment 
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failure were censored at the date of last follow up. Overall Survival (OS) was defined as the time 
from the first-line therapy to death. Patients alive were censored at the date of last follow-up. 
These 2 time-to-event endpoints were estimated by Kaplan-Meier method and compared 
according IMDC risk group using a log-rank test. Median TTF and median OS with 95% 
confidence interval (95%CI) were reported for each group. The cut-off date for the analyses was 
December, 31 2015. The statistical analyses were done with SAS software 9.4. (SAS Institute). 
 
Results 
 
All patients 
3DWLHQW¶VFKDUDFWHULVWLFV and overall survival 
We collected data from 91 mChRCC patients from 26 centers in 4 countries (France, UK, 
Italy and Australia). One patient was excluded because pathological diagnosis of ChRCC was 
uncertain (Figure 1). Patients had been diagnosed from July 1997 to April 2013. Median follow-
up from date of first metastasis was 6.1 years (range: 0-13.9). Patient and tumor characteristics 
are described in Table 1. Median age at diagnosis was 58 years (IQR: 49.0- 66.6) with a majority 
of men (64.4%, n= 58). Most patients had nephrectomy (92%, n=83). Median time from 
diagnosis to metastasis was 9.4 months (IQR: 0.7-37.7). Median time from metastasis to first-line 
treatment was 3.5 months (IQR: 1.1-13.4). In our cohort, 24.4% (n=22) had metachronous 
disease while 75.6% (n=68) were synchronous. Abdominal lymph nodes were the most common 
site of metastasis (41.6%, n=37) while lung (33.7%, n = 30) and liver metastases (19.1%, n =17) 
appeared to be less common. International Metastatic RCC Database Consortium (IMDC risk 
model) prognosis groups were favorable for 10.3% (n=6), intermediate for 69.0% (n=40) and 
poor for 20.7% (n=12) patients. The score was not available for 32 patients (35.6 %). The median 
OS from date of first metastasis was 37.9 months (95%CI 21.4 to 46.8). 
 
Patients treated with targeted therapy 
From 90 mChRCC patients, 68 patients received medical treatment, mostly TT (n=64), or 
other systemic therapy: Interferon alone (n=2), vinflunine or hormonal therapy (one each). In 
addition, 22 patients never received systemic therapy and were treated with surgery alone on 
oligometastatic site and/or close follow up only to delay systemic therapy (Figure 1).  Among the 
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64 patients treated with TT, 3 were excluded from the analysis because of missing data. The 
median follow-up for 61 treated patients from date of first line of treatment was 4.1 years (range: 
1.1-7.7). The IMDC risk model was analyzed in 72.1% (n= 44) of 61 patients: 2.3% (n=1) 
patients was in favorable prognosis group, 77.3% (n=34) were in intermediate prognosis group 
and 20.5% (n=9) in poor prognosis group. The score was not available for 17 patients. 
 
Type of treatment 
The different types of TT are reported in table 3.  In first line, 50 (82.0%) patients 
received AA while 11 (18.0%) patients received mTOR. Second line therapy was administered in 
30 (49.2%) patients and third line in 11(18.0%) patients. As second line of TT, 14 patients were 
treated with AA (46.7%) and 16 (53.3%) with mTOR.  
 
Response rate 
Response rate among 61 treated patients is described in table 2: CR: 1.9% (n=1), PR: 
23.1% (n=12), SD: 44.2% (n=23) and PD: 30.8 (16%) (9 had missing data). The ORR was 
CR/PR: 25.0 %. The distribution of ORR was not significantly different between AA: CR/PR: 
28.9% (n=13), SD: 42.2% (n=19) and PD: 28.9% (n=13) and mTOR: CR/PR: 0.0% (n=0), 7.7% 
(n=4) and PD: 5.8% (n=3) (p=0)LVKHU¶VH[DFWWHVW 
 
Time to Treatment Failure 
Time to Treatment Failure was calculated for 61 patients. The median TTF from date of first-line 
therapy for mChRCC was 7.2 months (95%CI: 4.1-9.5). Median TTF was 8.7 months (95%CI: 
5.2-10.9) and 1.9 months (95%CI: 1.0-6.0) respectively for the group treated with AA and mTOR 
inhibitors (Figure 2A). Median TTF for patients was 8.0 months (95%CI: 4.1-13.6) and 2.3 
months (95%CI: 0.7-8.0) p=0.001, according to IMDC risk model for intermediate and poor 
prognosis respectively (Figure 2B). We performed a stratified log-rank test to compare the 
targeted therapies (AA and mTOR) while controlling the effect of the IMDC score. No 
significant difference between AA and mTOR was observed with p= 0.2589 for TTF. 
 
 
Overall Survival 
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Median overall survival was 20.8 months (95%CI: 11.6-35.2) in treated population (70.5%, 43 
deaths). Median overall survival was 22.9 months (95%CI: 17.8-49.2) for the group treated with 
AA and 3.2 months (95%CI: 2.3-Not Evaluable) with mTOR inhibitors (Figure 2C),. As 
expected, the median overall survival was longer in patients with intermediate prognosis 
according to IMDC risk model (22.8 months 95CI%:13.7-82.4) compared to patients with poor 
prognosis (4.3 months 95%CI: 1.1-35.2) (p=0.0043, log rank test) (Figure 2D). We performed a 
stratified log-rank test to compare the targeted therapies (AA and mTOR) while controlling the 
effect of the IMDC score. No significant difference between AA and mTOR was observed with 
p= 0.5520 for OS. 
 
 
Discussion 
We report the largest series of patients with mChRCC treated with TT.  
 Firstly, observation of the scarcity of mChRCC and overall prognosis for ChRCC is 
consistent with prior reports both in the localized and metastatic setting. In 2016 a clinical based 
cohort study with meta-analysis reported a five-year OS rates for ChRCC and ccRCC of 90.3 and 
75.3 %, respectively (p < 0.001)13.  Metastatic ChRCC  is a very rare entity, according to large 
surgical cohorts6±9. Higher potential for distant metastases has been associated with sarcomatoid 
change and microscopic tumor necrosis14.  
Secondly, the lack of standardization in mChRCC is related to the fact that for several 
decades, nccRCC has been considered as a global entity. More recently, three randomized phase 
2 trials reported on nccRCC (Supplementary Table 1). Two dedicated randomized phase 2 
compared for the first time everolimus and sunitinib in patients with metastatic nccRCC14,15. In 
the first one (ESPN) among 72 patients, median PFS in first-line therapy was 6.1 (95%CI: 4.2-
9.4) months with sunitinib and 4.1 (95% CI: 2.7-10.5) with everolimus and median overall 
survival (OS) was 16.2 (95%CI: 14.2-NA) with sunitinib and 14.8 (95%CI: 8.0-23.4) with 
mTOR, respectively (p = 0.18)14. The second one (ASPEN), among 108 patients, with similar 
design, median PFS of 8.3 (80%CI:5.8-11.4) months with sunitinib versus 5.6 (80%CI:5.5-6.0) 
months with everolimus; hazard ratio (HR) was 1.41 (80%CI: 1.03-1.92) with no significance 
difference (p =0.16) 15. Median OS was 31.5 (80%CI: 14.8-NR) months with sunitinib versus 
13.2 (80%CI: 9.7-37.9) with everolimus.  
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In these studies, chromophobe patients accounted respectively for 12/72 and 16/108 patients. 
RECORD-3, a randomized phase 2 trials in metastatic RCC, comparing the sequence of 
everolimus followed by sunitinib at progression to the opposite sequence, enrolled both ccRCC 
and nccRCC patients16. In the subgroup analysis of 66 patients with nccRCC, everolimus did not 
yield better results than sunitinib as first-line therapy, median PFS were 5.1 and 7.2 months, 
respectively, (HR: 1.54; 95%CI: 0.86-2.75), but mChRCC only accounted for 2% and 3% of 
patients in each arm respectively.  
Before these randomized data, seldom phase III enrolled non ccRCC.  In 2007,  Hudes¶ study 
suggested that interesting responses were seen with temsirolimus in nccRCC17; among the 73 
patients with nccRCC, median OS was 11.6 months (95%CI: 8.4-14.5) vs 4.3 (95%CI: 3.2-7.3) 
with IFN alone18.  Most of the activity of TT in nccRCC report was initially reported in 
Expanded Access Programs (EAPs). Stadler reported in nccRCC subgroup (n=202) analysis of 
sorafenib EAP a median PFS of 24 weeks19, and Beck reported a median PFS of 5.7 months 
(95%CI: 4.5-6.7) for papillary subtype and of 4.0 months (95%CI: 2.8-4.8) for sarcomatoid 
features  (n=241 nccRCC)20. Within the Sunitinib EAP (n=4349), Gore reported in nccRCC 
subgroup (n=588)  a median  PFS of 7.8 months (95%CI: 6.3, 8.3) vs 10.9 (95%CI: 10.3, 11.2) 
months with ccRCC and a median OS of 13.4 months (95%CI: 10.7, 14.9) vs 18.4 months 
(95%CI: 17.4, 19.2)  in the entire population21.  
 However overall survival wit nccRCC has previously been reported as widely variable 
with distinct pathological entities harboring different prognosis. Before the TT era, Motzer 
reported an overall survival of 9.4 months for all non±clear-cell cohort while it was, 29 months 
for ChRCC, 11 months for collecting duct, and 5.5 months for papillary subtype22. In the TT era, 
the large report from IMDC real world evidence confirmed this heterogeneity.  In the subgroup 
analyses from Kroeger study, median OS was 12.8 months (95%CI: 11.0-16.1 months) for all 
non±clear-cell cohort12. In ChRCC median OS was 27.1 months (95%CI: 12.6-75.3 months), and 
it was 14.0 months (95%CI: 10.9-17.1 months), and 10.1 months (95%CI: 5.1-13.2 months) in 
pRCC and unRCC, respectively. Furthermore, this study demonstrates the applicability of the 
IMDC prognostic model in nccRCC treated with first line TT (VEGF and mTOR inhibitors): 
median OS of the 3 IMDC risk groups were 31.4 months (95%CI: 14.2-78.3 months), 16.1 
months (95%CI: 12.5-18.7 months), and 5.1 months (95%CI: 2.7-7.1 months) respectively.  
In our study median OS was 22.8 months (95%CI: 13.7-82.4) in intermediate prognosis risk 
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group and 4.3 months (95%CI: 1.1-35.2) in poor prognosis risk group (p=0.0043, log rank test) 
(Figure 1D). As only one patient had favorable prognosis risk group, he was excluded from this 
analysis. For first-line therapy in WKH.URHJHU¶VVWXG\, median TTF for nccRCC treated with TT 
was 7.8 months (95%CI: 7.2-8.1 months) and 4.2 months (95%CI: 3.7-5.2 months) in ccRCC and 
nccRCC, respectively.  Overall survival from Kroeger¶s cohort of 37 mChRCC was 27.1 months 
(95%CI: 12.6-75.3).  Similarly, in the retrospective study cohort from Choueiri et al median OS 
was 19.4 months in a mixed cohort of pRCC and ChRCC patients treated with sunitinib23.  
In our study, overall survival was 20.8 months (95%CI: 11.6-35.2) for patients treated 
with TT and median overall survival for the 90 patients was long with 37.9 months (CI95%: 
21.4-46.8) from diagnosis of metastatic disease.   
In the current study, we report that patients who received a first line AA have a better median 
TTF than patients who received mTOR inhibitors as first line (8.7 months vs1.9 months, 
p=0.0005, log rank test); and similarly they display longer median overall survival outcomes with 
AA.  The short survival of patients with mTOR in this retrospective cohort is explained by the 
fact that among the 11 patients treated with mTOR inhibitors,  6 belonged to the poor IMDC risk 
model group, one was intermediate risk and four had missing data about IMDC risk model score. 
At time of analysis 8/11 (72.8%) had died including 7 deaths within the first month of TT, 
potentially explaining this extremely short OS. 
A very recent cohort from Keizman et al investigated clinical outcome with TT for 
mChRCC within 36 patients from 10 centers across 4 countries24.  Metastatic ChRCC patients 
were individually matched to metastatic ccRCC patients by HENG risk, nephrectomy/smoking 
status, pre-treatment neutrophil to lymphocyte ratio, use of angiotensinogen system inhibitors, 
dose reduction/treatment interruption, and hypertension. Treatment outcome was not significantly 
different between metastatic ChRCC and ccRCC patients: median PFS was 10 versus 9 months 
(HR: 1.4; p=0.6). Median overall survival was 26 versus 25 months (HR: 1.15; p=0.7).  
Our study is not without limitations inherent to its retrospective nature and the major 
imbalance between AA and mTOR populations that prevents us to draw any conclusion on the 
specific role of mTOR inhibition in this setting.  The vast majority of our mChRCC cohort 
(81.9%) was treated with AA as first line; this led to this attrition bias related to the fact that a 
treatment with mTOR in first line was associated to poor prognosis fetaures in our study. 
Nevertheless, we believe that our cohort  (i) provide an exclusive large cohort of mChRCC 
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treated with TT to a benchmark  prognosis for future trial in this rare disease; (ii) highlight the 
activity of VEGF inhibition in this population in line with recent trials; (iii) illustrate the ability 
of collaborative groups to  investigate  rare renal tumors. 
 
Conclusion 
Metastatic ChRCC is a rare entity with no specific TT recommended. We provide the 
largest cohort, to date, of metastatic ChRCC treated with TT, mostly VEGF inhibition and 
illustrate the ability of academic consortium to investigate rare histologies.  Emerging data from 
the ChRCC genomic landscape may provide insight for more attractive TT in selected patients25. 
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Table 1: Patients¶ and tumor characteristics for all patients (n=90) and for patients treated by 
targeted therapy (n=61) 
 
Characteristics All patients 
(n=90) 
 
N (%) 
Patients receiving systemic 
targeted therapy (n=61)* 
 
N (%) 
Sex 
 Male 
 Female 
 
58 (64.4) 
32 (35.6) 
 
36 (59.0) 
25 (41.0) 
Age at diagnosis (years) 
 Median (IQR) 
 
58 (49 ± 66) 
 
57 (49 ± 63) 
KPS 
 80% 
 <80% 
 Missing 
 
56 (76.7) 
17 (23.3) 
17 
 
40 (75.5) 
13 (24.5) 
8 
Number of metastases 
 0-1 
 >1 
 Missing  
 
45(50.6) 
44(49.4) 
1 
 
27 (44.0) 
34 (55.7) 
0 
IMDC Risk modelÁ 
 0 
 1-2 
 3 
 Missing 
 
6 (10.3) 
40 (69.0) 
12 (20.7) 
32 
 
1 (2.3) 
34 (77.2) 
9 (20.5) 
17 
MSKCC£ 
 0 
 1 
 2 
 3 
 Missing 
 
10 (17.5) 
23 (40.4) 
14 (24.6) 
10 (17.5) 
33 
 
4 (9.3) 
20 (46.5) 
12 (27.9) 
7 (16.3) 
18 
Prior nephrectomy  
 No  
 Yes 
 
7(7.8) 
83 (92.2) 
 
4 (6.6) 
57 (93.4) 
Grade  
 1  
 2 
 3 
 4 
 Missing  
 
3(4.4) 
11 (16.2) 
32 (47.1) 
22 (32.4) 
22 
 
1 (2.0) 
9 (18.0) 
23 (46.0) 
17 (34.0) 
11 
 
*Beyond the 64 patients treated by systemic therapy 3 patients were excluded for missing data 
IQR: Interquartile range, Á IMDC = International Metastatic Renal Cell Carcinoma Database 
Consortium, £ MSKCC = Memorial Sloan Kettering Cancer Center. 
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Table 2: Best Response Rates, Time to treatment failure and Overall Survival in patients treated 
by targeted therapy (n=61) 
 
 Treated patients (n=61)* 
 AA mTOR All 
BR** 
CR/PR/SD/PD (%) 
1/12/19/13 
2.22/26.7/42.2/28.9 
0/0/4/3 
0/57.1/42.9 
1/12/23/16 
1.9/23.0/44.2/30.8 
ORR** 
CR+PR/SD/PD (%) 
13/19/13 
28.9/42.2/28.9 
0/4/3 
0/57.1/42.9 
13/23/16 
25.0/44.2/30.8 
No of deaths 35 8 43 
Median TTF (95%CI) 8.7 (5.2-10.9) 1.9 (1.0-6.0) 7.2 (4.1-9.5) 
Median OS (95%CI) 22.9 (17.8-49.2) 3.2 (2.3-NE) 20.8 (11.6-35.2) 
 
* Three patients were excluded for missing data, AA: antiangiogenic, mTOR: mTOR inhibitors. 
** Nine patients were excluded from BR and ORR analysis for missing data, BR = best response, 
CR =complete response, PR= partial response, SD = stable disease, PD = progression disease, 
ORR = objective response rate, CI = confidence interval; NE = not evaluable; TTF = time to 
treatment failure, OS = overall survival
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Table 3: Type of targeted treatment for 61 treated patients 
 
Targeted treatment N (%) 
Anti angiogenic 50 (81.9) 
 Sunitinib 40 (65.7) 
 Pazopanib 2 (3.2) 
 Sorafenib 5 (8.2) 
 IFN_bevacizumab 1 (1.64) 
 Bevacizumab based combination 2 (3.28) 
mTOR inhibitors 11(18.0) 
 Temsirolimus 4(6.7) 
 Everolimus 7(11.5) 
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Table 4: Metastatic site for entire cohort at systemic therapy initiation* 
 
Metastatic site N=89 (%) 
Abdominal nodes 37 (41.6) 
Lung metastasis 30 (33.7) 
Bone metastasis 20 (22.4) 
Mediastinal nodes 17 (19.1) 
Liver metastasis 17 (19.1) 
Brain metastasis 5 (5.6) 
Others (peritoneal relapse for majority) 28 (31.5) 
 
*: 1 patient has missing data for details of metastatic sites 
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Supplementary Table 1: Clinical outcomes described of mChRCC in literature 
 
 
References 
 
Trial design 
 
N 
mChrcc(%) 
Median OS 
(95% CI) (months) 
Median PFS 
(95% CI) (months) 
 
nccRCC ChRCC nccRCC ChRCC 
 
AA mTOR AA m TOR AA mTOR AA mTOR  
Motzer RJ et al. 
RECORD-3 Phase II randomized trial 
comparing sequential first-line everolimus and second-line sunitinib versus first-
line sunitinib and second-line everolimus in patients with metastatic renal cell 
carcinoma. 
J Clin Oncol 2014 
open-label, 
randomised 
phase 2 
11/207 
 
- - - - 7.2 (5.4-
13.8) 
5.1 (2.6-
7.9) 
- - 
Armstrong AJ et al 
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell 
carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. 
Lancet Oncol. 2016 
open-label, 
randomised 
phase 2 
16/108 31.5 
(14.8-
NR) 
13.2 
(9.7-
37.9) 
NS NS 8.3 
(80%5.8-
Â 
5.6 
(80%5.5-
6.0)  
5.5 (80% 
3.2±19.7) 
11.4 
(80%5.7±
19.4) 
Tannir et al 
ESPN Everolimus Versus Sunitinib Prospective Evaluation in 
Metastatic Non±Clear Cell Renal Cell Carcinoma (ESPN): 
A Randomized Multicenter Phase 2 Trial 
randomized 
phase 2 
12/72 16.2 14.8 31.6 (14.2±
NA) 
25.1 (4.7±
NA) 
6.1 (4.2-
9.4) 
4.1 (2.7-
10.5); 
8.9 (2.9-
20.1) 
NA 
Kroeger N et al. 
.Metastatic non-clear cell renal cell carcinoma treated with targeted therapy 
agents: characterization 
of survival outcome and application of the International mRCC Database 
Consortium criteria. 
Cancer 2013 
Retrospective 
study 
37 - - 27.1 (12.6-
75.3) 
- TTF= 4.2 
(3.7-5.2) 
- - - 
Gore ME et al. 
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an 
expanded-access trial. 
Lancet Oncol 2009 
Expendanded 
Acces 
Program 
NA 
 
13.4 
(10.7-
14.9) 
- - - 7.8 (6.3-
8.3) 
- - - 
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Tannir NMet al. 
A phase 2 trial of sunitinib in 
patients with advanced non-clear cell renal cell carcinoma. 
Eur Urol 2012 
Single arm 
phase 2 
 16.8 
(10.7-
26.3) 
 
- - - 2.7 (1.4-
5.4) 
- - - 
Lee J-Let al. 
Multicenter phase II study of sunitinib 
in patients with non-clear cell renal cell carcinoma. 
Ann Oncol 2012 
Single arm 
phase 2 
3 NR but 
25.6 (8.4 
-42.9) 
expected 
- - - 6.4( 4.2-
8.6) 
- - - 
Molina AM et al. 
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell 
carcinoma. 
Invest New Drugs 2012. 
 
Single arm 
phase 2 
2 - - - - 5.5 (2.5-
7.1) 
- - - 
Koh Y et al. 
Phase II trial of everolimus for the 
treatment of nonclear-cell renal cell carcinoma. 
Ann Oncol 2013 
Single arm 
phase 2 
8 - 14.0 - 21.6 - 5.2 
 
- 13.1 
Keizman D et al 
Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated 
With Sunitinib 
The Oncologist. 2016 
Retrospective 
study 
36 - - 26 (HR: 
1.15p=0.7) 
- - - 10 (HR: 
1.4; 
p=0.6).  
- 
Choueiri TK et al. 
Efficacy of sunitinib and 
sorafenib in metastatic papillary and chromophobe renal cell carcinoma. 
J Clin Oncol. 2008 
Retrospective 
study 
12 19.6 - NA - 8.6  - 10.6 - 
Voss MH et al. 
Treatment outcome with mTOR 
inhibitors for metastatic renal cell carcinoma with nonclear and 
sarcomatoid histologies. 
Ann Oncol 2014 
Retrospective 
study 
NA - 8.7 - - - 2.9 - - 
Dutcher JP et al. 
Effect of temsirolimus versus interferon-alpha on outcome of patients with 
Exploratory 
subgroup 
12 - 11.6 (8.9- 
14.5) 
- - - 7 (3.9- 8.9) - - 
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advanced renal cell carcinoma of different tumor histologies. 
Med Oncol 2009 
analyses from 
phase 3 
ARCC 
NA:  not assessable; TTF: Time To Treatment Failure; HR: Hazard ratio; NR: not reached; NS: not shown.
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Figure 1: Flow-chart 
 
 
 
AA: antiangiogenic, mTOR: mTOR inhibitors. 
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Figure 2: Unadjusted Kaplan-Meier estimation of (i) time to treatment failure in the first line 
targeted therapy according to type of targeted therapy (AA and mTOR) (A) and IMDC risk 
criteria (B) (ii)overall survival according to type of targeted therapy (AA and mTOR) (C) and 
IMDC risk criteria (D) in targeted treated patient (n=61)* 
 
A 
 
B 
 
C D 
 
 
* For IMDC risk model we did not report the TTF and OS for group with favorable prognosis 
because it represents only one patient.AA: antiangiogenic, mTOR: mTOR inhibitors. 
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